Saturday - November 23, 2024
AstraZeneca: Tagrisso Approved in the US for Patients With Unresectable, Stage III EGFR-Mutated Lung Cancer
September 27, 2024
WILMINGTON, Delaware, Sept. 27 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release:

* * *

Based on LAURA Phase III trial results which showed TAGRISSO extended median

progression-free survival by more than three years

* * *

AstraZeneca's TAGRISSO (osimertinib)​ has been approved in the US for the treatment of adult patients with unresectable, Stage III epidermal growth factor receptor-mutated ( . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products